Savillex, LLC has completed its acquisition of Entegris, Inc.’s Life Sciences Fluid Management business, adding a portfolio of single-use products used in bioprocessing and pharmaceutical manufacturing. Savillex is based in Eden Prairie, Minnesota, and Entegris is based in Billerica, Massachusetts.
The acquired business includes Aramus bags and PE bags, single-use assemblies, and components used across discovery, clinical and commercial manufacturing. Savillex said the acquisition expands its life sciences offerings with a broader portfolio of high-performance single-use solutions.
Savillex said customers can expect expanded single-use solutions, additional technical expertise and enhanced capabilities to support applications from early-stage research through commercial manufacturing. The company said the combination is intended to help customers simplify increasingly complex bioprocessing workflows.
The transaction also brings the Life Sciences Fluid Management team and its high-purity fluid management technologies into Savillex. The company said the acquired portfolio is complementary to its existing Savillex, Containment and Bioprocessing offerings.
Executive comments
Eric Giesing, chief executive officer of Savillex, said the Life Sciences Fluid Management business has built a strong reputation in high-purity single-use bioprocessing and that the Aramus product line is a natural fit alongside Savillex’s other offerings. He said the acquisition expands the portfolio and enables Savillex to deliver a broader range of solutions to biopharmaceutical and pharmaceutical customers.
Giesing also said Savillex is pleased to welcome the team behind the business and will continue investing in technologies that help customers accelerate development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the acquisition creates an opportunity to bring a broader portfolio of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the acquired portfolio complements Savillex’s existing capabilities, and the combined business will continue to provide innovative solutions while expanding support for partners across drug development.
Bedi said the combined business is intended to help customers bring new medicines to patients around the world.
Strategy and transaction details
Savillex said the acquisition advances its strategy of delivering industry-leading solutions for the life sciences market. The company said it remains committed to investing in innovation, quality and customer partnerships as it expands its portfolio to meet the evolving needs of biopharmaceutical and pharmaceutical manufacturers worldwide.
Financial terms of the transaction were not disclosed. EC M&A in New York served as financial advisor to Savillex, and Sidley Austin LLP in Chicago served as legal counsel.